Feed / BIO

Bio-Rad Laboratories, Inc.

BIO

Healthcare · 379.85 +0.9% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Bio-Rad Laboratories, Inc.'s move is being confirmed by its market group.

BIO accounts for 10.8% of the group's measured movement across 9.2 effective names. raw member direction is mixed; 10 of 10 SPY-adjusted paths align to the upside. Capital-flow agreement is 39%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveAligned contributor#5 of 10 by movement share
Group movement share10.8%Absolute path energy—not portfolio weight
Relative path+1.20%aligned
Effective breadth9.2 / 10broad
Relative alignment10/10upside path · 0 counter-moving
Capital-flow agreement39%not yet clean
SEQUENCE READ

BIO was the first measured mover. BIO crossed its material path threshold at 10:45 ET. CRL, SHC, RGEN followed.

What changed
  • Net income increased 16.9% versus the comparable filing period.
  • Revenue decreased 0.1% versus the comparable filing period.
EVIDENCE COVERAGE

5 of 10 members in Healthcare Diagnostics are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 7 of 10 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as BRKR begins moving with the group.

Invalidation: The live read weakens if participation falls to 3 of 10 members or fewer.

Watch this read

Who this business touches

The relationships behind BIO

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

SOAGYFiling-linked nameinvesteeApr 30, 2026 ▾

“The change in the fair market value primarily resulted from the recognition of holding losses of $727.7 million in the first quarter of 2026 compared to holding gains of $29.0 million in the first quarter of 2025 on our investment in Sartorius.”

ABTAbbott LaboratoriescompetitorFeb 13, 2026 ▾

“Major competitors for our products in the Clinical Diagnostics segment include Abbott Laboratories, Becton Dickinson, bioMérieux, Danaher, DiaSorin, Werfen, QuidelOrtho, Roche, Siemens Healthineers, Thermo Fisher Scientific and Tosoh.”

Depended on by

QDELQuidelOrtho CorporationcompetitorFeb 19, 2026 ▾

“Some of our principal competitors include, among others, Abbott Laboratories, bioMérieux, Bio-Rad, Danaher, Diasorin, Hologic, Qiagen, Revvity, Roche, Siemens Healthineers, Thermo Fisher Scientific, Waters Corporation (acquired BD Diagnostics division) and We…”

Filing peers

TXGTECHEMBC

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 11 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

BIO is currently a Leader in the organic co-movement group Healthcare Diagnostics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.